We discuss here the rapid progress of stem cell therapy in myocardial infarction. In particular, we focus on the issue of transdifferentiation as a "hallmark" of the stem cell's potential to replace damaged cells of the heart. A study by Henning and colleagues in this issue of Cell Transplantation supports the alternative notion of a nontransdifferentiation-mediated protection of the heart as an equally robust mechanism underlying the therapeutic potential of stem cells.
Myocardial infarction is the common cause of conges-cells (and hematopoietic stem cells) using a catheter attached to their coronary arteries. Compared with the tive heart failure, which afflicts approximately 5 million patients in the United States. Worldwide, about 23 mil-damaged hearts of patients who did not undergo this transplant regimen, the transplanted patients' hearts dis-lion are affected by heart failure. The long-standing dogma is that following an episode of heart attack, the played significantly increased contraction and enhanced ability to pump blood. This small-scale clinical trial heart is permanently crippled and cannot repair itself, ultimately succumbing to a fatal heart failure. To date, prompted other centers around the world to follow suit. Indeed, by this year, at least 400 heart patients have treatment options for myocardial infarction are limited and provide minimal restorative modality, if any.
been transplanted with bone marrow cells with encouraging preliminary results. Accumulating evidence now provides exciting therapeutic opportunities for healing the damaged hearts.
These laboratory and clinical studies set the pace for rigorous experiments into stem cell therapy for myocar-Dr. Valhalla and colleagues demonstrated that oxygendeprived hearts of mice could be rescued by transplant-dial infarction. There are, however, opponents to this quite radical treatment. The major arguments center ing stem cells derived from their own bone marrow (17) . Robust survival of the green fluorescent protein-labeled upon the safety and mechanisms underlying such restoration of heart functions. A recent study reports unex-transplanted cells coincided with production of heart muscle proteins, as well as restoration of some of the pected side effects in patients enrolled in a stem cell trial (11). Similarly, laboratory results question the trans-heart's function. This provocative observation led to the view that an adult's hematopoietic stem cells, which differentiation ability of hematopoietic cells (1,13,15). These reports highlight the absence of formation of new normally give rise to blood, could change their fate and transdifferentiate into producing an entirely different heart muscle in the transplanted hearts. Nonetheless, despite the lack of evidence of transdifferentiation, im-cell lineage, such as heart muscle (2,16).
Equally compelling was the clinical evidence reported provement in the animals' heart function was observed (1). This observation suggests mechanisms, other than by Dr. Strauer and colleagues (20) . After a heart attack, patients were transplanted with their own bone marrow transdifferentiation, are responsible for stem cell graft-726 STERN, HESS, AND BORLONGAN mediated functional recovery, including cell fusion (9), grafts' functional effects and minimize their side effects.
In the end, we may never fully recognize the mecha-graft-or host-derived angiogenesis (18) or vasculogenesis (21, 24) , and upregulation of trophic factors (3).
nisms underlying transplant-induced healing of the heart, but if stem cell therapy is proven safe and effective, clin-A major limiting factor to hematopoietic stem cell transplantation is the source of these stem cells. In this ical trials seem justified-of course, with extreme caution especially in the case of patients who are faint of issue of Cell Transplantation, Dr. Henning and colleagues recognized this limitation and thus embarked on heart. investigating the feasibility and efficacy of human um- for the treatment of acute myocardial infarction (8). Of note, HUCB mononuclear cells contain hematopoietic REFERENCES and mesenchymal progenitor cells, which are many fold greater than similar cells in bone marrow (4). HUCB The possibility to regenerate and to restore function anisms that mediate the functional effects of stem cell
